TerminatedNCT00748566
One-Year Trial Of Oral Ziprasidone In Patients With Metabolic Syndrome
Medication studyAges 18–65CanadaSchizophrenia
Understand this study
Who could participate?
Listed age limits: 18 years to 65 years.
- Listed locations
- Calgary and 31 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateDecember 2008
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 172
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Canada
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00748566
- Official title
Show the full official title
A One-Year, Phase IV, Open-Label, Non-Comparative Trial Of The Effect Of Ziprasidone HCL On Metabolic Syndrome Risk Factors In Patients With Psychotic Disorders
Recruitment & locations
TerminatedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Calgary · Medicine Hat · Red Deer
20 more locations
- Penticton
- Victoria
- Winnipeg
- Bathurst
- St. John's
- Halifax
- Sydney
- Burlington
- Chatham
- Greater Sudbury
- Kingston
- London
- Markham
- Mississauga
- Ottawa
- Toronto
- Windsor
- Montreal
- Verdun
- Saskatoon
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Does this study involve medication?
Yes. The study involves medication, including Ziprasidone HCL (oral).
Who can participate?
Listed age limits: 18 years to 65 years.
Is this study still recruiting?
The registry lists this study as terminated.
